We like both spinoff and parent

Article Excerpt

ELANCO ANIMAL HEALTH INC. $33 (New York symbol ELAN; Shares outstanding: 365.6 million; Market cap: $12.1 billion; No dividend paid; Takeover Target Rating: Medium; www.elanco.com) makes medications for both livestock and companion animals (pets). On September 21, 2018, Eli Lilly (New York symbol LLY) set Elanco up as a separate company and sold 19.8% of its shares through an initial public offering at $24 each. Eli Lilly plans to then spin off the remaining 80% by handing out those shares to its investors. Animal health is a stable, expanding business, both for livestock and pets. What’s more, unlike human drugs, animal medicines are not subject to the complex U.S. human-health system and its insurance-company reimbursements. Clinical trials to introduce new drugs are also not as onerous as those for human medications. Elanco is a buy, but for only aggressive investors. Eli Lilly & Co. is also a buy. buy…